Previous Close | 0.3719 |
Open | 0.6838 |
Bid | 0.8862 x 3100 |
Ask | 0.8820 x 1300 |
Day's Range | 0.5900 - 0.9580 |
52 Week Range | 0.2750 - 18.6000 |
Volume | |
Avg. Volume | 3,686,539 |
Market Cap | 33.418M |
Beta (5Y Monthly) | -0.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -19.0060 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.10 |
Subscribe to Yahoo Finance Plus to view Fair Value for EVFM
Shares of Evofem Biosciences Inc. soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced. Experts have speculated that the court's decision could lead to restrictions on birth control in the future although that was not included in Friday's decision. Evofem makes a non-hormonal gel that is used about an hour before sex to prevent pregnancy by controlling pH levels, which in turn lessens the mobility of sperm. It is prescribed by health c
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.
NEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Evofem Biosciences, Inc.